In response to the current COVID-19 pandemic, EU-OPENSCREEN screening and chemistry partners are contributing their expertise and resources to a vast number of activities, from searching antiviral drugs for the SARS-CoV-2 with focus on drug repurposing, to the development and implementation of diagnostic tests and screening patients’ samples for the presence of SARS-CoV-2.
To support this research effort, EU-OPENSCREEN ERIC has made available its Bioactives library of 2.500 compounds, which are modulating over 1000 known targets. The library consists of 654 approved drugs and 368 highly selective probes, used for screening projects at our partner sites. For more information, contact us at email@example.com.
The efforts partner sites are taking in combating the current outbreak are listed below:
Main contact: firstname.lastname@example.org
Dr. Petr Bartůněk and his team are participating in the Coronatest-hackathon (the Czech academic initiative) to screen for the presence of SARS-CoV-2 in the Czech population. In particular:
Main contact: Mark.Broenstrup@helmholtz-hzi.de
Main contact compound screening and profiling: Ursula.Bilitewski@helmholtz-hzi.de
Prof. Mark Brönstrup and Prof. Ursula Bilitewski are undertaking several screening and chemical optimization campaigns. In particular:
Main contact: Bernhard.Ellinger@itmp.fraunhofer.de
Dr. Bernhard Ellinger, Dr. Phil Gribbon, Dr. Sheraz Gul, Dr. Mira Grättinger, Dr. Ole Pless, and Dr. Andrea Zaliani, using their 4Ds (drugs, data, devices, diagnostics) competency in Drug Repurposing, Medical Data Science for COVID-19 data, and validation and pilot studies for COVID-19 tools, are active in:
Please click here to download all ITMP activities related to the of SARS-CoV-2/ COVID-19 research.
Main contact: email@example.com
Dr. Olga Genilloud and her team are looking for new therapeutic and diagnostic solutions for SARS-CoV-2:
FUNDACION MEDINA is looking for partners with BSL3 virus inhibition assays and infection animal models to test the antiviral activity of MEDINA malaria hits (Spanish Tropical Diseases network), and natural product analogs of drugs recently reported active on SARS-CoV-2 targets.
Main contact: firstname.lastname@example.org
Dr. María J. Vicent is involved in collaborative research activities related to:
In this approach one of the tasks of CIPF is to carry out a screening to identify new drugs capable of compensating COVID-19 induced mitochondrial loss and metabolic disfunction.
Main contact: email@example.com
Prof. Mabel Loza, is involved in research activities geared towards drug repurposing against virus key targets and protein production for vaccines. BioFarma Research group is involved:
More information can be found here.
To get in contact with the BioFarma research Group please write to firstname.lastname@example.org.
Main contact: email@example.com
Prof. Päivi Tammela and Dr. Jani Sareela, are performing screening for both target and cell-based assays, also with full virus in collaboration with the Department of Virology, Department of Bacteriology and Immunology, Faculty of Medicine, and Helsinki University Hospital (HUS). The HTB unit offers access to:
Main contact: firstname.lastname@example.org
Prof. Aigars Jirgensons and Dr. Osvalds Pugovics, as EU-OPENSCREEN medicinal chemistry site, are dealing with:
OSI is open to collaboration offering their drug discovery/ technology development expertise. Particularly, OSI is seeking for partners with capabilities and expertise in antiviral infection models.
Main contact: email@example.com
Prof. Dr. Zbigniew J. Leśnikowski, is taking part in research on the search for new therapeutic and diagnostic methods for SARS-CoV-2 as well as basic research on the molecular aspects of the physiology and pathology of the virus. IMB PAS is involved in:
Main contact: firstname.lastname@example.org
Dr. Radosław Pilarski, Dr. Jacek Kolanowski, Dr. Magdalena Otrocka and their teams are actively working on a vast array of activities to combat the COVID-19 pandemic with a focus on the search of new therapeutic and diagnostic solutions for SARS-CoV-2. Currently, the institute is:
ICBH PAS offers priority access for COVID-19 related projects to their infrastructure and expertise in:
Main contact: email@example.com
Prof. Dr. Piotr Zielenkiewicz and his team are taking part in: